VectivBio AG
Works in GI & liver · Immunology · Renal & urogenital · Women's health
VectivBio AG is a clinical trial sponsor. It has 2 active clinical trials with 282 planned participants, in GI & liver, Immunology, Renal & urogenital and Women's health. Since 2021 it has completed 6 trials and stopped 1 early.
Trial track record · since 2021
Financials
No SEC filings under this name. The company is private, listed abroad, or files under a parent.
Fundraising
No SEC Form D filings under this name. A private round is only public when the company files one.
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
On the market · 0 products
No marketed products under this name.
Questions about VectivBio AG
VectivBio AG is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 282 planned participants, in GI & liver, Immunology, Renal & urogenital, Women's health. Since 2021 it has completed 6 trials and stopped 1 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with VectivBio AG; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-08-04.
Products come from FDA's drug application database and, for vaccines, cell and gene therapies and blood products, FDA's Purple Book of licensed biologics; checked 2026-09-28.
Approve Suite is not affiliated with VectivBio AG.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.